Newsletter Tool

Featured Story

FDA slaps clinical hold on AstraZeneca cancer drug amid heart safety scare in combo test

By Ben Adams

We found out, via a small and almost unnoticed ClinicalTrials.gov update today, that AstraZeneca suspended trial work on its experimental blood cancer drug AZD5991. Now, we have learned that things are in fact bleaker for the therapy.

Biogen, with sales falling sharply, posts 'obviously disappointing' Aduhelm sales of $300K, CEO Vounatsos says

By Kevin Dunleavy

Biogen sales were sliding ahead of the controversial approval for Alzheimer's drug Aduhelm. On Wednesday morning, Biogen revealed a stunning number—$300,000—in third-quarter sales for the medicine, once hailed as a first-of-its-kind breakthrough drug.

White House says it's prepped to deliver millions of kids' COVID vaccines to pediatricians, children's hospitals, pharmacies

By Dave Muoio

The Biden administration that it has secured enough shots for all 28 million U.S. kids ages five to 11 and, contingent on regulatory authorization, will work with tens of thousands of providers and community organizations to put shots in arms.

Medtronic issues EU safety warning for Percept PC deep brain stimulation implant

By Andrea Park

Medtronic identified an issue in which its Percept PC deep brain stimulation implant may stop working and need to be removed after an implanted patient undergoes a cardioversion.

Novavax struggling to meet quality standards in COVID-19 vaccine production push: report

By Joseph Keenan

Novavax, which reaped $1.6 billion from the federal government last year to develop and manufacture a COVID-19 vaccine, is reportedly struggling to meet quality standards.

F-star shoots for the moon with massive $1.35B J&J biobucks deal for 5 bispecifics

By Kyle LaHucik

Add Johnson & Johnson's Janssen Biotech to the list of Big Pharmas lining up at the doors of 2011 Fierce 15 winner F-star Therapeutics. The $17.5 million upfront, $1.35 billion biobucks pact grants Janssen an exclusive license to up to five novel bispecific antibodies.

Pfizer strong-armed governments in COVID-19 vaccine supply talks, report says

By Eric Sagonowsky

Pfizer is playing a leading role in producing vaccines against COVID-19, but new documents released by Public Citizen shine a light on the company's aggressive tactics when negotiating supply deals.

Drug overdoses surged during the pandemic. Providers are thinking outside the box to combat the opioid crisis

By Anastassia Gliadkovskaya

Drug overdose deaths rose 30% in 2020. But experts say the U.S. lags in offering evidence-based treatment to address addiction. Fierce Healthcare spoke to providers who are trying to revolutionize the way forward.

Abbott's COVID test sales make comeback thanks to delta-driven demand

By Conor Hale

After weathering a nearly billion-dollar dip in rapid COVID testing revenues earlier this year, Abbott’s BinaxNow antigen test sales rebounded following the COVID-19 resurgence due to the delta variant.

Princeton and MIT gene-editing pioneers uncover clues for improving CRISPR and other tools

By Angus Liu

Scientists at Princeton and MIT, including gene-editing pioneer David Liu, used a new screening method called Repair-seq to identify pathways that affect different outcomes in CRISPR/Cas9, prime editing and base editing. The findings could help design more accurate and efficient gene-editing systems, they say.

PM Tracker